↓ Skip to main content

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study

Overview of attention for article published in Investigational New Drugs, August 2005
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#48 of 1,168)
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

news
1 news outlet
policy
1 policy source
patent
7 patents

Citations

dimensions_citation
87 Dimensions

Readers on

mendeley
39 Mendeley
Title
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study
Published in
Investigational New Drugs, August 2005
DOI 10.1007/s10637-005-1446-y
Pubmed ID
Authors

Nicolas Tsavaris, Christos Kosmas, Helias Skopelitis, Panagiotis Gouveris, Petros Kopteridis, Dioynissis Loukeris, Frantzeska Sigala, Alexandra Zorbala-Sypsa, Evangelos Felekouras, Efstathios Papalambros

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 3%
Unknown 38 97%

Demographic breakdown

Readers by professional status Count As %
Other 8 21%
Student > Doctoral Student 5 13%
Student > Ph. D. Student 4 10%
Researcher 3 8%
Professor 3 8%
Other 5 13%
Unknown 11 28%
Readers by discipline Count As %
Medicine and Dentistry 14 36%
Biochemistry, Genetics and Molecular Biology 3 8%
Agricultural and Biological Sciences 3 8%
Nursing and Health Professions 1 3%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Other 4 10%
Unknown 13 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 December 2023.
All research outputs
#2,276,356
of 22,757,090 outputs
Outputs from Investigational New Drugs
#48
of 1,168 outputs
Outputs of similar age
#3,744
of 57,245 outputs
Outputs of similar age from Investigational New Drugs
#2
of 8 outputs
Altmetric has tracked 22,757,090 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,168 research outputs from this source. They receive a mean Attention Score of 4.7. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 57,245 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.